Please ensure Javascript is enabled for purposes of website accessibility

Why Amarin Corporation Shot 7.7% Higher Today

By Eric Volkman - Feb 1, 2021 at 6:25PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

It's all about the incentives.

What happened

Amarin (AMRN -2.04%) enjoyed a 7.7% ride skyward on Monday. This was on the back of a regulatory document filed after market hours on Friday detailing some new incentives for top management.

So what

Amarin disclosed in the document that it has drafted and implemented an Executive Severance and Change of Control Plan. This is a set of measures beefing up severance payments -- in addition to other benefits -- for the biotech's top executives.

Piggy bank with stethoscope.

Image source: Getty Images.

In the event of termination of employment "without 'Cause' or by a participant for 'Good Reason'," in Amarin's words, the company's CEO (currently John Thero) would still receive their base salary for 24 months. Among other perks, they would also receive continued enrollment in Amarin's group healthcare plan and be allowed to vest outstanding equity awards.

Meanwhile, Amarin's executive, senior vice presidents, and vice presidents will also be granted comparable severance arrangements, albeit at more modest levels than the CEO's arrangement.

Those perks would be guaranteed for shorter periods with other forms of termination and in other circumstances.

Now what

While the company has lately suffered patent setbacks with Vascepa, its star drug for the treatment of cardiovascular disease, the medicine has vast potential outside of the U.S., especially in the European Union where an estimated 85 million people suffer from this condition.

Keeping top management comfortable and secure should help with C-suite morale and thus overall company stability. It might also serve as a sort of poison pill, or at least a disincentive, to a potential acquirer.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Amarin Corporation plc Stock Quote
Amarin Corporation plc
AMRN
$1.44 (-2.04%) $0.03

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
327%
 
S&P 500 Returns
116%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/20/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.